1
|
Molyneux G, Andrews M, Sones W, York M, Barnett A, Quirk E, Yeung W, Turton J. Haemotoxicity of busulphan, doxorubicin, cisplatin and cyclophosphamide in the female BALB/c mouse using a brief regimen of drug administration. Cell Biol Toxicol 2010; 27:13-40. [PMID: 20589437 DOI: 10.1007/s10565-010-9167-1] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2009] [Accepted: 03/18/2010] [Indexed: 10/19/2022]
Abstract
Many anticancer drugs are myelotoxic and cause bone marrow depression; however, generally, the marrow/blood returns to normal after treatment. Nevertheless, after the administration of some anti-neoplastic agents (e.g. busulphan, BU) under conditions as yet undefined, the marrow may begin a return towards normal, but normality may not be achieved, and late-stage/residual marrow injury may be evident. The present studies were conducted to develop a short-term mouse model (a 'screen') to identify late-stage/residual marrow injury using a brief regimen of drug administration. Female BALB/c mice were treated with BU, doxorubicin (DOX), cisplatin (CISPLAT) or cyclophosphamide (CYCLOPHOS) on days 1, 3 and 5. In 'preliminary studies', a maximum tolerated dose (MTD) for each drug was determined for use in 'main studies'. In main studies, mice were treated with vehicle (control), low and high (the MTD) dose levels of each agent. Necropsies were performed, and blood parameters and femoral/humeral nucleated marrow cell counts (FNCC/HNCC) were assessed on six occasions (from days 1 to 60/61 post-dosing). Late-stage/residual changes were apparent in BU-treated mice at day 61 post-dosing: RBC, Hb and haematocrit were reduced, mean cell volume/mean cell haemoglobin were increased and platelet and FNCC counts were decreased. Mice given DOX, CISPLAT and CYCLOPHOS, in general, showed no clear late-stage/residual effects (day 60/61). It was concluded that a brief regimen of drug administration, at an MTD, with assessment at day 60/61 post-dosing was a suitable short-term method/screen in the mouse for detecting late-stage/residual marrow injury for BU, a drug shown to exhibit these effects in man.
Collapse
Affiliation(s)
- Gemma Molyneux
- Department of Pharmacology, Centre for Toxicology, The School of Pharmacy, University of London, 29/39 Brunswick Square, London, UK.
| | | | | | | | | | | | | | | |
Collapse
|
2
|
Heimpel H. When should the clinician suspect a drug-induced blood dyscrasia, and how should he proceed? Eur J Haematol Suppl 2009; 60:11-5. [PMID: 8987235 DOI: 10.1111/j.1600-0609.1996.tb01639.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Blood dyscrasias account for only a minor fraction of all adverse drug reactions (ADRs), but are relevant because of their relatively high morbidity and mortality. For the majority of drugs, the magnitude of risk is low enough to remain undetected until wider distribution of the drug takes place. Thus, only post-marketing studies, carried out with appropriate methodology and sufficient statistical power, will allow the risk of serious haematological side-effects of new drugs to be ascertained. Publication of carefully studied and thoroughly described single case studies and reports to registries are necessary to detect new associations between drugs and blood dyscrasias, while only large cohort or case-control studies are suited to quantify the risks. Physicians managing a newly detected blood dyscrasia should be aware that it may be drug-induced. They should assess the exact diagnosis, obtain and thoroughly document a detailed exposure history and follow the blood counts after withdrawal of all potentially relevant agents. The recognition and appropriate management of the problem in individual cases is the basis for both effective patient care and the quality of subsequent pharmaco-epidemiological evaluation.
Collapse
Affiliation(s)
- H Heimpel
- Department of Internal Medicine (Haematology/Oncology), University of Ulm, Germany
| |
Collapse
|
3
|
Turton JA, Fagg R, Sones WR, Williams TC, Andrews CM. Characterization of the myelotoxicity of chloramphenicol succinate in the B6C3F1 mouse. Int J Exp Pathol 2006; 87:101-12. [PMID: 16623754 PMCID: PMC2517354 DOI: 10.1111/j.0959-9673.2006.00460.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Chloramphenicol (CAP) is haemotoxic in man, inducing two types of toxicity. First, a dose-related, reversible anaemia with reticulocytopenia, sometimes seen in conjunction with leucopenia and thrombocytopenia; this form of toxicity develops during drug treatment. The second haemotoxicity is aplastic anaemia (AA) which is evident in the blood as severe pancytopenia. AA development is not dose-related and occurs weeks or months after treatment. We wish, in the longer term, to investigate CAP-induced AA in the busulphan-pretreated mouse. However, as a prelude to that study, we wanted to characterize in detail the reversible haemotoxicity of CAP succinate (CAPS), administered at high dose levels in the mouse, and follow the recovery of the bone marrow in the post-dosing period. Female B6C3F1 mice were gavaged with CAPS at 0, 2500 and 3500 mg/kg, daily, for 5 days and sampled (n = 5) at 1, 7, 14 and 21 days post-dosing. Blood, bone marrow and spleen samples were analysed and clonogenic assays carried out. At day 1 post-dosing, at both CAPS dose levels, decreases were seen in erythrocytes and erythrocyte precursors; marrow erythroid cells were reduced. Reductions were also evident in splenic nucleated cell counts, blood high fluorescence ratio (HFR) reticulocyte counts and total reticulocyte counts; burst-forming units-erythroid and colony-forming units-erythroid showed decreases. At day 7 post-dosing (2500 mg/kg CAPS), there was regeneration of erythrocyte production, with marked splenic erythropoietic activity, and raised blood HFR reticulocytes. At day 7, at 3500 mg/kg CAPS, erythrocyte and reticulocyte parameters remained depressed. At 14 days post-dosing (2500 mg/kg CAPS), many erythrocyte parameters had returned to normal; at 3500 mg/kg CAPS, there was erythroid regeneration. By 21 days post-dosing, at both CAPS dose levels, most erythrocytic parameters were equivalent to control values. For leucocyte parameters, there was some depression at day 1 post-dosing (at both CAPS dose levels) and signs of recovery at day 7. At days 14 and 21 post-dosing, most leucocyte parameters were close to control values. Marrow smears at day 1 post-dosing (at both CAPS dose levels) showed vacuolation of early normoblasts, of myeloid and of monocytic precursors. We conclude that the administration of CAPS at 2500 and 3500 mg/kg for 5 days induced significant myelotoxicity in female B6C3F1 mice, with cessation of erythropoiesis at day 1 post-dosing; recovery was seen over the following 7/14 days. The blood HFR reticulocyte count was a precise indicator of CAPS-induced depressive effects and subsequent recovery. It is concluded that the administration of five daily doses of CAPS at 2500 and 3500 mg/kg to the female B6C3F1 mouse induces an anaemia with reticulocytopenia, in conjunction with leucopenia, in the immediate post-dosing period; no evidence was seen at 21 days post-dosing of peripheral blood pancytopenia or a hypocellular/acellular bone marrow, which are both characteristic features of AA in man.
Collapse
Affiliation(s)
- John A Turton
- Centre for Toxicology, Department of Pharmacology, The School of Pharmacy, University of London, London, UK.
| | | | | | | | | |
Collapse
|
4
|
Turton JA, Sones WR, Andrews CM, Pilling AM, Williams TC, Molyneux G, Rizzo S, Gordon-Smith EC, Gibson FM. Further development of a model of chronic bone marrow aplasia in the busulphan-treated mouse. Int J Exp Pathol 2006; 87:49-63. [PMID: 16436113 PMCID: PMC2517350 DOI: 10.1111/j.0959-9673.2006.00455.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2005] [Accepted: 09/28/2005] [Indexed: 11/27/2022] Open
Abstract
Aplastic anaemia (AA) in man is an often fatal disease characterized by pancytopenia of the peripheral blood and aplasia of the bone marrow. AA is a toxic effect of many drugs and chemicals (e.g. chloramphenicol, azathioprine, phenylbutazone, gold salts, penicillamine and benzene). However, there are no widely used or convenient animal models of drug-induced AA. Recently, we reported a new model of chronic bone marrow aplasia (CBMA = AA) in the busulphan (BU)-treated mouse: eight doses of BU (10.50 mg/kg) were administered to female BALB/c mice over a period of 23 days; CBMA was evident at day 91/112 post-dosing with significantly reduced erythrocytes, platelets, leucocytes and nucleated bone marrow cell counts. However, mortality was high (49.3%). We have now carried out a study to modify the BU-dosing regime to induce CBMA without high mortality, and investigated the patterns of cellular responses in the blood and marrow in the post-dosing period. Mice (n = 64/65) were dosed 10 times with BU at 0 (vehicle control), 8.25, 9.0 and 9.75 mg/kg over 21 days and autopsied at day 1, 23, 42, 71, 84, 106 and 127 post-dosing (n = 7-15); blood and marrow samples were examined. BU induced a predictable bone marrow depression at day 1 post-dosing; at day 23/42 post-dosing, parameters were returning towards normal during a period of recovery. At day 71, 84, 106 and 127 post-dosing, a stabilized, late-stage, nondose-related CBMA was evident in BU-treated mice, with decreased erythrocytes, platelets and marrow cell counts, and increased MCV. At day 127 post-dosing, five BU-treated mice showed evidence of lymphoma. In this study, mortality was low, ranging from 3.1% (8.25 mg/kg BU) to 12.3% (9.75 mg/kg BU). It is concluded that BU at 9.0 mg/kg (or 9.25 mg/kg) is an appropriate dose level to administer (10 times over 21 days) to induce CBMA at approximately day 50-120 post-dosing.
Collapse
Affiliation(s)
- John A Turton
- Centre for Toxicology, Department of Pharmacology, School of Pharmacy, University of London, London, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Molyneux G, Gibson FM, Gordon-Smith EC, Pilling AM, Liu KC, Rizzo S, Sulsh S, Turton JA. The haemotoxicity of mitomycin in a repeat dose study in the female CD-1 mouse. Int J Exp Pathol 2005; 86:415-30. [PMID: 16309546 PMCID: PMC2517448 DOI: 10.1111/j.0959-9673.2005.00452.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2005] [Accepted: 09/14/2005] [Indexed: 11/29/2022] Open
Abstract
Mitomycin (MMC), like many antineoplastic drugs, induces a predictable, dose-related, bone marrow depression in man and laboratory animals; this change is generally reversible. However, there is evidence that MMC may also cause a late-stage or residual bone marrow injury. The present study in female CD-1 mice investigated the haematological and bone marrow changes induced by MMC in a repeat dose study lasting 50 days. Control and MMC-treated mice were dosed intraperitoneally on eight occasions over 18 days with vehicle, or MMC at 2.5 mg/kg, autopsied (n = 6-12) at 1, 7, 14, 28, 42 and 50 days after the final dose and haematological changes investigated. Femoral nucleated bone marrow cell counts and levels of apoptosis were also evaluated and clonogenic assays carried out; serum levels of FLT3 ligand (FL) were assessed. At day 1 post-dosing, MMC induced significant reductions in RBC, Hb and haematocrit (HCT) values, and there were decreases in reticulocyte, platelet, and femoral nucleated cell counts (FNCC); neutrophil, lymphocyte and monocyte values were also significantly reduced. On days 7 and 14 post-dosing, all haematological parameters showed evidence of a return towards normal values, but at these times, and at day 28, values for RBC and FNCC remained significantly reduced in comparison with controls. At days 42 and 50 post-dosing, many haematological parameters in MMC-treated mice had returned to control levels; however, there remained evidence of late-stage effects on RBC, Hb and HCT values, and FNCC also continued to be significantly decreased. Results for granulocyte-macrophage colony-forming units and erythroid colonies showed a profound decrease immediately post-dosing, but a return to normal values was evident at day 50. Serum FL concentrations demonstrated very significant increases in the immediate post-dosing period, but a return to normal was seen at day 50 post-dosing; a relatively similar pattern was seen in the number of apoptotic femoral marrow nucleated cells. The histopathological examination of kidney tissues from MMC animals at day 42 and 50 post-dosing showed evidence of hydronephrosis with cortical glomerular/tubular atrophy and degeneration. It is therefore concluded that MMC administered on eight occasions over 18 days to female CD-1 mice at 2.5 mg/kg induced profound changes in haematological and bone marrow parameters in the immediate post-dosing period with a return to normal levels at day 50 post-dosing; however, there was evidence of mild but significant late-stage/residual effects on RBC and FNCC, and on cells of the erythroid lineage in the bone marrow.
Collapse
Affiliation(s)
- Gemma Molyneux
- Department of Haematology, St George's Hospital Medical School, London, UK
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Haemotoxicity of chlorambucil in the Wistar Hanover rat with particular reference to bone marrow culture, marrow cell apoptosis and levels of FLT3 ligand. ACTA ACUST UNITED AC 2004. [DOI: 10.1007/s00580-004-0524-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
7
|
Turton JA, Andrews CM, Havard AC, Williams TC. Studies on the haemotoxicity of chloramphenicol succinate in the Dunkin Hartley guinea pig. Int J Exp Pathol 2002; 83:225-38. [PMID: 12641819 PMCID: PMC2517684 DOI: 10.1046/j.1365-2613.2003.00232.x] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2001] [Accepted: 09/12/2002] [Indexed: 11/20/2022] Open
Abstract
In man, chloramphenicol (CAP), induces two major haemotoxic effects. First, a reversible, dose-related reticulocytopenia and anaemia developing during treatment. Second, a non-dose-related aplastic anaemia (AA), developing weeks after treatment, is often irreversible and fatal. In previous studies, we developed a mouse model of the reversible reticulocytopenia/anaemia using CAP succinate (CAPS); attempts to induce AA in the mouse with CAPS were unsuccessful; in the rat, CAPS induced only minimal haemotoxicity. We therefore wished to investigate haematological changes caused by CAPS in a third rodent, particularly in relation to the induction of significant 'late stage' bone marrow depression (AA). Female guinea pigs were gavaged with CAPS in three experiments. In a dose ranging study, CAPS (at 2500 and 3500 mg/kg) was administered daily for 9 days, and blood examined at 1 day post dosing. CAPS induced increased erythrocyte values (an apparent haemoconcentration effect), and reduced reticulocytes and femoral marrow nucleated cell counts (FNCC). In a second experiment, CAPS was given at 333, 666 and 1000 mg/kg (13 days); haematological changes were compared with results from the initial study, with evidence of dose-related effects. In a final experiment, CAPS was administered (825 mg/kg, 16 days) and blood studied at 1, 12, 28 and 63 days post dosing. At day 1, erythrocyte values were decreased (NS), and reticulocytes and FNCC were reduced; the marrow was hypocellular with erythroid depletion. At 12 and 28 days, values returned towards the normal range. At 63 days, parameters were normal. Thus, CAPS (825 mg/kg for 16 days) induced changes comparable to the reversible bone marrow depression seen in man; but there was no evidence of 'late stage' (i.e. at 63 days) marrow depression, as would be seen in a developing or overt marrow aplasia (AA). The guinea pig (like the mouse) is a model for the early events, but is not a good model for CAP-induced AA in man.
Collapse
Affiliation(s)
- J A Turton
- Centre for Toxicology, Department of Pharmacology, The School of Pharmacy, University of London, 29/39 Brunswick Square, London WC1N 1AX, UK.
| | | | | | | |
Collapse
|
8
|
Deldar A, Stevens CE. Development and application of in vitro models of hematopoiesis to drug development. Toxicol Pathol 1993; 21:231-40. [PMID: 7692585 DOI: 10.1177/019262339302100216] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
In vitro models of hematopoiesis are used increasingly in investigative hematopathology. Such models complement in vivo animal testing and have been shown to be predictive for hematotoxicity associated with anticancer and antiviral agents in humans. In vitro models of hematopoiesis consist of short-term cloning assays for various hematopoietic progenitor cells and long-term functional assays for the marrow hematopoietic microenvironment. In our laboratories, the cloning assays have been used as investigative tools to study the pathogenetic mechanisms of drug-induced blood disorders and as screening systems to investigate the possible hematotoxic potential of candidate drugs in various animal species. Data in support of these applications are presented in this paper.
Collapse
Affiliation(s)
- A Deldar
- In Vitro Hematopoiesis Laboratory, Lilly Research Laboratories, Eli Lilly and Company, Greenfield, Indiana 46140
| | | |
Collapse
|
9
|
Twerdok LE, Trush MA. Neutrophil-derived oxidants as mediators of chemical activation in bone marrow. Chem Biol Interact 1988; 65:261-73. [PMID: 2837335 DOI: 10.1016/0009-2797(88)90111-1] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Neutrophil-derived oxidants have been implicated in both damage to biomolecules and the metabolic activation of xenobiotics. Since the bone marrow is a relatively neutrophil-rich tissue which is subject to xenobiotic toxicity, we have characterized the oxidant generating capability of neutrophilic cells isolated from femurs of male C57BL/6J mice. Addition of the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) to neutrophil preparations (70 +/- 5% ring neutrophils and metamyelocytes) elicited superoxide anion generation, as indicated by superoxide dismutase (SOD)-inhibitable acetylated cytochrome c reduction, and oxidant-dependent chemiluminescence (CL) from luminol or lucigenin. The interaction of benzo[a]pyrene-7,8-dihydrodiol (BP-diol), a proximate carcinogenic metabolite of benzo[a]pyrene (BP), with TPA-stimulated bone marrow neutrophils resulted in azide-inhibitable CL (90%) indicative of its myeloperoxidase-dependent oxidation to an excited-state intermediate. Covalent binding of [3H]BP-diol to exogenous DNA was similarly increased 3-fold in the presence of TPA-stimulated bone marrow neutrophils. Recently, our laboratory has shown that in addition to CL, TPA-stimulated human polymorphonuclear leukocytes can activate BP-diol to an intermediate which covalently binds to DNA and elicits mutagenicity in Salmonella typhimurium TA100. These observations combined with our current results suggest a possible role for neutrophil-derived oxidants in the mechanisms of chemically-induced bone marrow toxicity.
Collapse
Affiliation(s)
- L E Twerdok
- Department of Environmental Health Sciences, Johns Hopkins University, School of Hygiene and Public Health, Baltimore, MD 21205
| | | |
Collapse
|
10
|
Young GA, Croaker G, Vincent PC, Forrest P, Morris TC. The CFU-C assay in patients with neutropenia and, in particular, drug associated neutropenia. CLINICAL AND LABORATORY HAEMATOLOGY 1987; 9:245-53. [PMID: 3652636 DOI: 10.1111/j.1365-2257.1987.tb00088.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
One-hundred and four patients with a diagnosis of aplastic anaemia (28) or neutropenia (76) referred to our laboratory for assessment of granulopoiesis were studied. Bone marrow myeloid progenitor cell (CFU-C) frequency was measured and in 85 patients, inhibitor studies with either in-vitro drug addition or plasma co-culture were performed. Of 28 patients with aplastic anaemia, 22 (79%) had low numbers of CFU-C, while four (14%) had numbers within the normal range and two (7%) had elevated progenitor cell frequency. In contrast, of the 76 patients with neutropenia who were studied only 29 (38%) had low CFU-C numbers, 33 (43%) had a CFU-C frequency within the normal range and 14 (18%) had elevated CFU-C numbers. Thirty-nine patients had ingested potentially myelotoxic drugs and in eight of these it was possible to demonstrate drug associated inhibition of CFU-C proliferation in vitro. The drugs most commonly associated on a historical basis with myelosuppression were chloramphenicol, antimalarials, sulphonamides, anticonvulsants and nonsteroidal anti-inflammatory agents.
Collapse
Affiliation(s)
- G A Young
- Kanematsu Laboratories, Royal Prince Alfred Hospital, Camperdown, Australia
| | | | | | | | | |
Collapse
|
11
|
Abstract
Aplastic anaemia and agranulocytosis are uncommon but serious adverse effects of drug therapy. They result from an adverse interaction between the drug and the haemopoietic pathway in certain susceptible individuals. The nature of this idiosyncratic interaction differs for different drugs and possibly for different individuals. In some instances an immune mechanism might be implicated, in others the patient's cells might carry a genetic susceptibility to the drug, while yet other patients might metabolise the drug abnormally. The idiosyncratic nature of these effects has made their investigation difficult, but experimental studies have allowed some progress in our understanding. In a practical sense, however, responsibility for preventing these problems will remain with clinicians, who should be alert to the risks and revise their prescribing habits accordingly.
Collapse
|